Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.55 |
| ▸ | CTSG | P08311 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 4/20 | 0.50 |
| ▸ | MC4R | P32245 | 7/20 | 0.49 |
| ▸ | MC5R | P33032 | 7/20 | 0.49 |
| ▸ | MC3R | P41968 | 7/20 | 0.49 |
| ▸ | MC1R | Q01726 | 7/20 | 0.49 |
| ▸ | NNMT | P40261 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387473 | 0.95 | ITGB3 (0.59) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29420577 | 0.88 | KLKB1 (0.50) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29388360 | 0.83 | ELANE (0.53) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL13722938 | 0.80 | PLAU (0.50) | PLAUITGB3ITGB1ITGAVITGA5 | |
| Cyclorgdfv SCHEMBL25474158 | 0.79 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| Cyclorgdfv SCHEMBL29973120 | 0.79 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| Cyclorgdfv SCHEMBL19605549 | 0.79 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| Cyclorgdfv SCHEMBL19605449 | 0.79 | ITGB3 (0.58) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL25473422 | 0.79 | KDM4A (0.55) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL27423920 | 0.78 | MC4R (0.48) | ITGB3ITGB1ITGAVITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841964-A | Multi-epitope vaccine antigen based on BCG and application thereof | 新疆医科大学 | 2025-04-18 | — | — | CN | claimed |
| US-20250041381-A1 | Prophylactic Uses of Theta Defensins | UNIVERSITY OF SOUTHERN CALIFORNIA | 2025-02-06 | — | — | US | claimed |
| EP-4426330-A1 | PROPHYLACTIC USES OF THETA DEFENSINS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-09-11 | — | — | EP | claimed |
| US-20230270828-A1 | COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | BICT S.R.L. (IT) | 2023-08-31 | — | — | US | claimed |
| WO-2023081149-A1 | PROPHYLACTIC USES OF THETA DEFENSINS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-11 | — | — | WO | claimed |
| CN-122031654-A | Targeting delivery nano-carrier antibacterial protein, preparation method and application thereof | 海泰达生物科技(广州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12569535-B2 | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4643951-A2 | ANTI-CD3 ANTIBODIES AND USES THEREOF | Janssen Biotech, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-3802608-B1 | ANTI-CD3 ANTIBODIES AND USES THEREOF | JANSSEN BIOTECH INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250041381-A1 | Prophylactic Uses of Theta Defensins | UNIVERSITY OF SOUTHERN CALIFORNIA | 2025-02-06 | — | — | US | disclosed |
| US-20240309049-A1 | SYNTHETIC DNA BINDING DOMAIN PEPTIDES AND USES THEREOF | THE UNIVERSITY OF CHICAGO (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4426330-A1 | PROPHYLACTIC USES OF THETA DEFENSINS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4087555-A1 | METHODS OF USING ANDROGRAPHOLIDE, ORIDONIN AND ISOLIQUIRITIGENIN AND DERIVATIVES THEREOF | The Regents of The University of California (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4087555-A1 | METHODS OF USING ANDROGRAPHOLIDE, ORIDONIN AND ISOLIQUIRITIGENIN AND DERIVATIVES THEREOF | The Regents of The University of California (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-109248310-B | Blockade of inflammatory proteases using theta-defensins | 加利福尼亚大学董事会 | 2022-07-01 | — | — | CN | disclosed |
| CN-108135947-B | Materials and methods for enhancing immune response and skin and/or mucosal barrier function | 群体创新有限责任公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114630818-A | Protein-macromolecule conjugates and methods of use thereof | 北京轩义医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022104073-A1 | DEFENSINS AS INHIBITORS OF SARS-COV-2 INFECTION AND USES THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-05-19 | — | — | WO | disclosed |
| CN-114259441-A | Composition for improving skin micro-ecological environment and preparation method and application thereof | 科丝美诗(中国)化妆品有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022029577-A1 | COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | BICT S.R.L. (IT) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309049-A1 | SYNTHETIC DNA BINDING DOMAIN PEPTIDES AND USES THEREOF | DDB1, SSBP1, CNBP | PLAU 2596/4885ITGB3 4194/4885ITGB1 4592/4885 |
| US-12569535-B2 | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides | CFD, ARG1, IL1A | PLAU 1170/4885ITGB3 1135/4885ITGB1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.